Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.

Journal Article (Journal Article)

A total of 32 evaluable patients with measurable advanced colorectal carcinoma were treated with continuous-infusion alpha-difluoromethylornithine (DFMO) at a median daily dose of 8 g/m2 (range, 6-14 g/m2). DFMO was infused over 24 h daily for 28 days, followed by a rest period of 7 days. Of the 32 patients, 14 had received no prior chemotherapy. A total of 65 courses was given, with the median being 2 (range, 1-9 courses). None of the patients achieved a partial or complete response; however, 3 patients achieved a minor response and 14 had stable disease. The frequent toxic effects of DFMO included thrombocytopenia (which was dose-limiting), malaise, nausea, vomiting, reversible hearing loss, and diarrhea. Our data suggest that continuous-infusion DFMO therapy is feasible and results in only mild gastrointestinal toxicity. Although DFMO proved to be ineffective as a single agent in this trial, it could probably best be used in combination with cytotoxic agents known to enhance its antitumor activity in a preclinical setting.

Full Text

Duke Authors

Cited Authors

  • Ajani, JA; Ota, DM; Grossie, VB; Abbruzzese, JL; Faintuch, JS; Patt, YZ; Jackson, DE; Levin, B; Nishioka, K

Published Date

  • 1990

Published In

Volume / Issue

  • 26 / 3

Start / End Page

  • 223 - 226

PubMed ID

  • 2113439

International Standard Serial Number (ISSN)

  • 0344-5704

Digital Object Identifier (DOI)

  • 10.1007/BF02897204


  • eng

Conference Location

  • Germany